Orchid Pharma vs Peers
- Market cap
- ₹4,933 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹700.31 – ₹1,313.08
Orchid Pharma ranks 1st by market capitalisation among 1 Drug Manufacturers - Specialty & Generic companies tracked by ATS. Its largest peers are Orchid Pharma. Its P/E of 22.5 compares with a peer median of 22.5.
Orchid Pharma vs Drug Manufacturers - Specialty & Generic peers
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Orchid Pharma | 972.65 | -5.01% | 4,933 | 22.5 | 2.85 | 14.5% | +18.5% |
| Orchid Pharma | 972.65 | -5.01% | 4,933 | 22.5 | 2.85 | 14.5% | +24.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 9 October 2026. How this data is compiled.
Orchid Pharma peer comparison — frequently asked questions
Who are Orchid Pharma's competitors?
Orchid Pharma's listed peers in Drug Manufacturers - Specialty & Generic include Orchid Pharma, ranked here by market capitalisation.
How does Orchid Pharma's P/E compare with its peers?
Orchid Pharma trades at a P/E of 22.5, against a median of 22.5 across the 1 Drug Manufacturers - Specialty & Generic peers shown.
Which is the largest company among Orchid Pharma's peers?
By market capitalisation, the largest company in the group is Orchid Pharma at ₹4,933 crore, against ₹4,933 crore for Orchid Pharma.
Same Data For Peers
Trade Orchid Pharma With ATS
Track ORCHPHARMA live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.